Dipartimento di Scienze Sperimentali e Cliniche

Scuola di Medicina e Scienze della Salute - Università degli Studi "G. d'Annunzio" Chieti - Pescara

DISCOVERY & DEVELOPMENT OF MONOCLONAL ANTIBODIES AND ANTIBODY-DRUGS-CONJUGATED TO DIAGNOSE AND TO TREAT CANCER AND OTHER SEVERE DISEASES

MediaPharma srl is a Biotech Company focusing on discovery & development of monoclonal antibodies and antibody-drugs-conjugated to diagnose and to treat cancer and other severe diseases.
The Company, established in 2009 as a spin-off of the “G. d’Annunzio” University Foundation, is based in Chieti, Italy.
Academical Members of MediaPharma:from the Dept. of Experimental and Clinical Sciences:
Stefano Iacobelli – Founder and President,
Nicola Tinari – Cofounder and Senior Consultant R&D,
Other Cofounder: Raffaella Muraro, Clara Natoli, and Mauro Piantelli.
The Managing Team includes Riccardo Palumbo (Member of Board of Directors and Professor of Accounting at our University), Pier Giorgio Natali, Jean-Fred Sauniere, Antonio Zangrilli.

Product pipeline, research product catalogue, contacts, etc. at: http://www.mediapharma.it/

In addition to the development of therapeutic antibodies, current research interest includes the identification and the exploitation of diagnostic, prognostic and predictive markers (and marker clusters) in cancer.